Blood-based RNA test outperforms gold-standard Alzheimer's diagnostics
Circular Genomics has launched its CircPATH platform following a Nature Medicine study demonstrating that blood-based circular RNA biomarkers can predict Alzheimer's disease progression with greater accuracy than current clinical standards. The findings suggest a new, non-invasive path for identifying risk years before symptoms emerge.